《新股表现》再鼎医药(09688.HK)高开9.2%报613.5元
再鼎医药(09688.HK)暗盘平开报562元获承接,最高见586.5元,收582.5元高上市价3.7%;该股首挂开报613.5元,较上市价562元,高近9.2%,市前成交27.6万股。
再鼎医药(ZLAB.US)上周五於美股续升2.9%收79.33美元。
中概股再鼎医药总部位於上海,是一间创新型、立足研发及处於商业阶段生物制药公司,其致力於为全球患者生产包括肿瘤、抗感染及自体免疫性疾病领域的创新药物。该股已於2017年9月在纳指上市,今次来港作第二上市合共发售约1,056.41万股,其中约7.3%开发售获2.43倍超购,认购一手中签率50%;股份最终定价562元(招股最高发售价648元),料集资净额约57.3亿元,主要用作研发核心产品、为进行中和计划临床试验及管线中其他候选药物的准备中注册备案拨资、探索新的全球授权和合作机会等、用作持续投资和扩大公司内部研发产品管线及在全球招聘培训高端人才等。上市联席保荐人分别为摩通、高盛及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.